FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used to diagnose the detection of Ph-negative myeloproliferative blastoma. A set containing specific primers and fluorescence-labelled DNA probes is proposed. Primers have the following nucleotide composition (5'-3'-): JAK2-W-F, JAK2-W-R, JAK2-W-P, JAK2-M-F, JAK2-M-R, JAK2-M-P, CALR-l-F, CALR-l-R, MPL-K-F, MPL-K-R, CALR-1-P, MPL-K-P, CALR-2-F, CALR-2-R, MPL-L-F, MPL-L-R, CALR-2-P, MPL-L-P. In TaqMan probes on 5' end dyes are used: fluorescein (FAM) and chlorinated fluorescein (HEX). For extinction of fluorescence, Black Hole Quencher-1 (BHQ1) on 3' end is used. Also a diagnostic method of Ph-negative myeloproliferative blastoma is proposed, including a conduction of a real-time polymerase chain reaction.
EFFECT: group of inventions allows the simultaneous study of several mutations in one analytical series, which leads to the result in a shorter period of time; and also provides an accurate diagnosis of chronic Ph-negative myeloproliferative blastoma, allows to identify a group of patients with the presence of combined pathogenetic mutations.
2 cl, 3 dwg, 3 tbl, 1 ex
